

CORRECTED VERSION

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
10 March 2005 (10.03.2005)

PCT

(10) International Publication Number  
**WO 2005/020962 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 9/107**,  
31/337, 38/13

(21) International Application Number:  
PCT/IB2004/003077

(22) International Filing Date: 27 August 2004 (27.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
03292141.3 29 August 2003 (29.08.2003) EP  
60/498,663 29 August 2003 (29.08.2003) US

(71) Applicants (for all designated States except US): NOVA-  
GALI PHARMA SA [FR/FR]; 1, rue Pierre Fontaine,  
F-91000 Evry (FR). YISSUM RESEARCH DEVELOP-  
MENT COMPANY OF THE HEBREW UNIVERSITY  
OF JERUSALEM [IL/IL]; Hi Tech Park, Edmond Safra  
Campus, Givat Ram 91390 (IL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GARRIGUE, Jean-  
Sébastien [FR/FR]; 128, rue d'Estienne d'Orves, F-91370  
Verrieres le Buisson (FR). LAMBERT, Gregory [FR/FR];  
38 route des Gatines, F-91370 Verrieres le Buisson (FR).  
RAZAFINDRATSITA, Alain [MG/FR]; 166, rue Petit  
Leroy, F-94550 Chevilly Larue (FR). BENITA, Simon  
[IL/IL]; 33/3 Haarazim Street, 90805 Mevasseret Zion  
(IL).

(74) Agents: MARTIN, Jean-Jacques et al.; Cabinet Regim-  
beau, 20, rue de Chazelles, F-75847 Paris Cedex 17 (FR).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report

(48) Date of publication of this corrected version:

16 June 2005

(15) Information about Correction:

see PCT Gazette No. 24/2005 of 16 June 2005, Section II

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: SELF-NANOEMULSIFYING OILY FORMULATION FOR THE ADMINISTRATION OF POORLY WATER-SOLU-  
BLE DRUGS

(57) Abstract: A pharmaceutical composition in a form of an anhydrous self-nanoemulsifying oily formulation comprising: one  
or more therapeutic agent(s) which have low solubility in water or are water-insoluble, vitamin E, one co-solvent selected from  
propylene glycol and ethanol and mixture thereof one surfactant selected from tyloxapol and from mixture of tyloxapol and TPGS,  
and optionally, a bioenhancer.

WO 2005/020962 A1